Search

Your search keyword '"Meenhard Herlyn"' showing total 16 results
Start Over Author "Meenhard Herlyn" Publisher nature portfolio
16 results on '"Meenhard Herlyn"'

1. Cell state dependent effects of Bmal1 on melanoma immunity and tumorigenicity

Author

Xue Zhang, Shishir M. Pant, Cecily C. Ritch, Hsin-Yao Tang, Hongguang Shao, Harsh Dweep, Yao-Yu Gong, Rebekah Brooks, Patricia Brafford, Adam J. Wolpaw, Yool Lee, Ashani Weeraratna, Amita Sehgal, Meenhard Herlyn, Andrew Kossenkov, David Speicher, Peter K. Sorger, Sandro Santagata, and Chi V. Dang

Subjects
Science
Abstract

Abstract The circadian clock regulator Bmal1 modulates tumorigenesis, but its reported effects are inconsistent. Here, we show that Bmal1 has a context-dependent role in mouse melanoma tumor growth. Loss of Bmal1 in YUMM2.1 or B16-F10 melanoma cells eliminates clock function and diminishes hypoxic gene expression and tumorigenesis, which could be rescued by ectopic expression of HIF1α in YUMM2.1 cells. By contrast, over-expressed wild-type or a transcriptionally inactive mutant Bmal1 non-canonically sequester myosin heavy chain 9 (Myh9) to increase MRTF-SRF activity and AP-1 transcriptional signature, and shift YUMM2.1 cells from a Sox10high to a Sox9high immune resistant, mesenchymal cell state that is found in human melanomas. Our work describes a link between Bmal1, Myh9, mouse melanoma cell plasticity, and tumor immunity. This connection may underlie cancer therapeutic resistance and underpin the link between the circadian clock, MRTF-SRF and the cytoskeleton.

Published
2024
Full Text
View/download PDF

2. HRS phosphorylation drives immunosuppressive exosome secretion and restricts CD8+ T-cell infiltration into tumors

Author

Lei Guan, Bin Wu, Ting Li, Lynn A. Beer, Gaurav Sharma, Mingyue Li, Chin Nien Lee, Shujing Liu, Changsong Yang, Lili Huang, Dennie T. Frederick, Genevieve M. Boland, Guangcan Shao, Tatyana M. Svitkina, Kathy Q. Cai, Fangping Chen, Meng-Qiu Dong, Gordon B. Mills, Lynn M. Schuchter, Giorgos C. Karakousis, Tara C. Mitchell, Keith T. Flaherty, David W. Speicher, Youhai H. Chen, Meenhard Herlyn, Ravi K. Amaravadi, Xiaowei Xu, and Wei Guo

Subjects
Science
Abstract

Lack of CD8+ T-cell infiltration into solid tumors is associated with poor responsiveness to immune checkpoint therapy (ICT). Here, the authors show that blocking the phosphorylation of HRS to reduce the induction of immunosuppressive exosomes promotes CD8+ T-cell infiltration into tumors and enhances the efficacy of ICT in mouse melanoma models.

Published
2022
Full Text
View/download PDF

3. Persister state-directed transitioning and vulnerability in melanoma

Author

Heike Chauvistré, Batool Shannan, Sheena M. Daignault-Mill, Robert J. Ju, Daniel Picard, Stefanie Egetemaier, Renáta Váraljai, Christine S. Gibhardt, Antonio Sechi, Farnusch Kaschani, Oliver Keminer, Samantha J. Stehbens, Qin Liu, Xiangfan Yin, Kirujan Jeyakumar, Felix C. E. Vogel, Clemens Krepler, Vito W. Rebecca, Linda Kubat, Smiths S. Lueong, Jan Forster, Susanne Horn, Marc Remke, Michael Ehrmann, Annette Paschen, Jürgen C. Becker, Iris Helfrich, Daniel Rauh, Markus Kaiser, Sheraz Gul, Meenhard Herlyn, Ivan Bogeski, José Neptuno Rodríguez-López, Nikolas K. Haass, Dirk Schadendorf, and Alexander Roesch

Subjects
Science
Abstract

Slow-cycling melanoma persister cells are characterised by a high, reversible expression of H3K4 demethylase KDM5B. Here, the authors use genetic and chemical methods to enforce a permanent high expression of KDM5B and show that these cells transit to a melanocytic differentiated state and undergo cell cycle arrest.

Published
2022
Full Text
View/download PDF

4. Targeting SOX10-deficient cells to reduce the dormant-invasive phenotype state in melanoma

Author

Claudia Capparelli, Timothy J. Purwin, McKenna Glasheen, Signe Caksa, Manoela Tiago, Nicole Wilski, Danielle Pomante, Sheera Rosenbaum, Mai Q. Nguyen, Weijia Cai, Janusz Franco-Barraza, Richard Zheng, Gaurav Kumar, Inna Chervoneva, Ayako Shimada, Vito W. Rebecca, Adam E. Snook, Kim Hookim, Xiaowei Xu, Edna Cukierman, Meenhard Herlyn, and Andrew E. Aplin

Subjects
Science
Abstract

Mechanisms underlying tumor cell plasticity remain poorly understood. Here, the authors show the presence of a dormant-invasive SOX10- subpopulation in cutaneous melanoma that can be targeted by cIAP1/2 inhibitors.

Published
2022
Full Text
View/download PDF

5. Pathway signatures derived from on-treatment tumor specimens predict response to anti-PD1 blockade in metastatic melanoma

Author

Kuang Du, Shiyou Wei, Zhi Wei, Dennie T. Frederick, Benchun Miao, Tabea Moll, Tian Tian, Eric Sugarman, Dmitry I. Gabrilovich, Ryan J. Sullivan, Lunxu Liu, Keith T. Flaherty, Genevieve M. Boland, Meenhard Herlyn, and Gao Zhang

Subjects
Science
Abstract

Gene signatures that predict response to immune checkpoint blockade (ICB) therapies in melanoma have been based on preclinical models and pre-treatment samples. Here the authors develop pathway-based signatures to predict ICB response in melanoma using on-treatment samples, leading to improved performance.

Published
2021
Full Text
View/download PDF

6. Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidatesfor targeted treatment

Author

Hua Sun, Song Cao, R. Jay Mashl, Chia-Kuei Mo, Simone Zaccaria, Michael C. Wendl, Sherri R. Davies, Matthew H. Bailey, Tina M. Primeau, Jeremy Hoog, Jacqueline L. Mudd, Dennis A. Dean, Rajesh Patidar, Li Chen, Matthew A. Wyczalkowski, Reyka G. Jayasinghe, Fernanda Martins Rodrigues, Nadezhda V. Terekhanova, Yize Li, Kian-Huat Lim, Andrea Wang-Gillam, Brian A. Van Tine, Cynthia X. Ma, Rebecca Aft, Katherine C. Fuh, Julie K. Schwarz, Jose P. Zevallos, Sidharth V. Puram, John F. Dipersio, The NCI PDXNet Consortium, Brandi Davis-Dusenbery, Matthew J. Ellis, Michael T. Lewis, Michael A. Davies, Meenhard Herlyn, Bingliang Fang, Jack A. Roth, Alana L. Welm, Bryan E. Welm, Funda Meric-Bernstam, Feng Chen, Ryan C. Fields, Shunqiang Li, Ramaswamy Govindan, James H. Doroshow, Jeffrey A. Moscow, Yvonne A. Evrard, Jeffrey H. Chuang, Benjamin J. Raphael, and Li Ding

Subjects
Science
Abstract

Patient-derived xenograft models (PDX) have been extensively used to study the molecular and clinical features of cancers. Here the authors present a cohort of 536 PDX models from 25 cancers, as well as their genomic and evolutionary profiles and their suitability for clinical trials.

Published
2021
Full Text
View/download PDF

7. Tumor-infiltrating mast cells are associated with resistance to anti-PD-1 therapy

Author

Rajasekharan Somasundaram, Thomas Connelly, Robin Choi, Hyeree Choi, Anastasia Samarkina, Ling Li, Elizabeth Gregorio, Yeqing Chen, Rohit Thakur, Mohamed Abdel-Mohsen, Marilda Beqiri, Meaghan Kiernan, Michela Perego, Fang Wang, Min Xiao, Patricia Brafford, Xue Yang, Xiaowei Xu, Anthony Secreto, Gwenn Danet-Desnoyers, Daniel Traum, Klaus H. Kaestner, Alexander C. Huang, Denitsa Hristova, Joshua Wang, Mizuho Fukunaga-Kalabis, Clemens Krepler, Fang Ping-Chen, Xiangyang Zhou, Alexis Gutierrez, Vito W. Rebecca, Prashanthi Vonteddu, Farokh Dotiwala, Shashi Bala, Sonali Majumdar, Harsh Dweep, Jayamanna Wickramasinghe, Andrew V. Kossenkov, Jorge Reyes-Arbujas, Kenisha Santiago, Tran Nguyen, Johannes Griss, Frederick Keeney, James Hayden, Brian J. Gavin, David Weiner, Luis J. Montaner, Qin Liu, Lukas Peiffer, Jürgen Becker, Elizabeth M. Burton, Michael A. Davies, Michael T. Tetzlaff, Kar Muthumani, Jennifer A. Wargo, Dmitry Gabrilovich, and Meenhard Herlyn

Subjects
Science
Abstract

Immune checkpoint therapies (ICT) are promising for treating various cancers, but response rates vary. Here the authors show, in mouse models, that tumor-infiltrating mast cells colocalize with regulatory T cells, coincide with local reduction of MHC-I and CD8 T cells, and is associated with resistance to ICT, which can be reversed by c-kit inhibitor treatment.

Published
2021
Full Text
View/download PDF

8. Pre-clinical modeling of cutaneous melanoma

Author

Vito W. Rebecca, Rajasekharan Somasundaram, and Meenhard Herlyn

Subjects
Science
Abstract

Despite the new targeted and immunotherapies for metastatic melanoma, several patients show therapeutic plateau. Here, the authors review the current pre-clinical models of cutaneous melanoma and discuss their strengths and limitations that may help with overcoming therapeutic plateau.

Published
2020
Full Text
View/download PDF

9. B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma

Author

Johannes Griss, Wolfgang Bauer, Christine Wagner, Martin Simon, Minyi Chen, Katharina Grabmeier-Pfistershammer, Margarita Maurer-Granofszky, Florian Roka, Thomas Penz, Christoph Bock, Gao Zhang, Meenhard Herlyn, Katharina Glatz, Heinz Läubli, Kirsten D. Mertz, Peter Petzelbauer, Thomas Wiesner, Markus Hartl, Winfried F. Pickl, Rajasekharan Somasundaram, Peter Steinberger, and Stephan N. Wagner

Subjects
Science
Abstract

The regulation of tumor inflammation is incompletely understood and the role of B cells is unclear. Here, the authors show that a specific subtype of B cells is induced in melanoma and required to recruit T lymphocytes and elicit inflammation.

Published
2019
Full Text
View/download PDF

10. Loss of Phd2 cooperates with BRAF V600E to drive melanomagenesis

Author

Shujing Liu, Gao Zhang, Jianping Guo, Xiang Chen, Jingce Lei, Kan Ze, Liyun Dong, Xiangpeng Dai, Yang Gao, Daisheng Song, Brett L. Ecker, Ruifeng Yang, Caitlin Feltcher, Kai Peng, Cheng Feng, Hui Chen, Rebecca X. Lee, Heddy Kerestes, Jingwen Niu, Suresh Kumar, Weiting Xu, Jie Zhang, Zhi Wei, James S. Martin, Xiaoming Liu, Gordon Mills, Yiling Lu, Wei Guo, Lunquan Sun, Lin Zhang, Ashani Weeraratna, Meenhard Herlyn, Wenyi Wei, Frank S. Lee, and Xiaowei Xu

Subjects
Science
Abstract

Prolyl hydroxylase domain protein 2 (PHD2) regulates cellular response to hypoxia. Here the authors show that PHD2 is downregulated in melanoma and that PHD2 depletion, in a mouse model, promotes the progression of benign melanocytic lesions into melanoma, via activation of the Akt/mTOR signaling cascade.

Published
2018
Full Text
View/download PDF

11. Author Correction: Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment

Author

Hua Sun, Song Cao, R. Jay Mashl, Chia-Kuei Mo, Simone Zaccaria, Michael C. Wendl, Sherri R. Davies, Matthew H. Bailey, Tina M. Primeau, Jeremy Hoog, Jacqueline L. Mudd, Dennis A. Dean, Rajesh Patidar, Li Chen, Matthew A. Wyczalkowski, Reyka G. Jayasinghe, Fernanda Martins Rodrigues, Nadezhda V. Terekhanova, Yize Li, Kian-Huat Lim, Andrea Wang-Gillam, Brian A. Van Tine, Cynthia X. Ma, Rebecca Aft, Katherine C. Fuh, Julie K. Schwarz, Jose P. Zevallos, Sidharth V. Puram, John F. Dipersio, The NCI PDXNet Consortium, Brandi Davis-Dusenbery, Matthew J. Ellis, Michael T. Lewis, Michael A. Davies, Meenhard Herlyn, Bingliang Fang, Jack A. Roth, Alana L. Welm, Bryan E. Welm, Funda Meric-Bernstam, Feng Chen, Ryan C. Fields, Shunqiang Li, Ramaswamy Govindan, James H. Doroshow, Jeffrey A. Moscow, Yvonne A. Evrard, Jeffrey H. Chuang, Benjamin J. Raphael, and Li Ding

Subjects
Science
Published
2022
Full Text
View/download PDF

12. Tumor-associated B-cells induce tumor heterogeneity and therapy resistance

Author

Rajasekharan Somasundaram, Gao Zhang, Mizuho Fukunaga-Kalabis, Michela Perego, Clemens Krepler, Xiaowei Xu, Christine Wagner, Denitsa Hristova, Jie Zhang, Tian Tian, Zhi Wei, Qin Liu, Kanika Garg, Johannes Griss, Rufus Hards, Margarita Maurer, Christine Hafner, Marius Mayerhöfer, Georgios Karanikas, Ahmad Jalili, Verena Bauer-Pohl, Felix Weihsengruber, Klemens Rappersberger, Josef Koller, Roland Lang, Courtney Hudgens, Guo Chen, Michael Tetzlaff, Lawrence Wu, Dennie Tompers Frederick, Richard A. Scolyer, Georgina V. Long, Manashree Damle, Courtney Ellingsworth, Leon Grinman, Harry Choi, Brian J. Gavin, Margaret Dunagin, Arjun Raj, Nathalie Scholler, Laura Gross, Marilda Beqiri, Keiryn Bennett, Ian Watson, Helmut Schaider, Michael A. Davies, Jennifer Wargo, Brian J. Czerniecki, Lynn Schuchter, Dorothee Herlyn, Keith Flaherty, Meenhard Herlyn, and Stephan N. Wagner

Subjects
Science
Abstract

Resistance to BRAFV600E inhibitors often occurs in melanoma patients. Here, the authors describe a potential mechanism of acquired drug resistance mediated by tumor-associated B cells-derived IGF-1.

Published
2017
Full Text
View/download PDF

13. Author Correction: Loss of Phd2 cooperates with BRAF V600E to drive melanomagenesis

Author

Shujing Liu, Gao Zhang, Jianping Guo, Xiang Chen, Jingce Lei, Kan Ze, Liyun Dong, Xiangpeng Dai, Yang Gao, Daisheng Song, Brett L. Ecker, Ruifeng Yang, Caitlin Feltcher, Kai Peng, Cheng Feng, Hui Chen, Rebecca X. Lee, Heddy Kerestes, Jingwen Niu, Suresh Kumar, Weiting Xu, Jie Zhang, Zhi Wei, James S. Martin, Xiaoming Liu, Gordon Mills, Yiling Lu, Wei Guo, Lunquan Sun, Lin Zhang, Ashani Weeraratna, Meenhard Herlyn, Wenyi Wei, Frank S. Lee, and Xiaowei Xu

Subjects
Science
Abstract

The original version of this Article contained an error in the spelling of the author Brett L. Ecker, which was incorrectly given as Brett Ecker. This has now been corrected in both the PDF and HTML versions of the Article.

Published
2019
Full Text
View/download PDF

14. Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidatesfor targeted treatment

Author

Li Chen, Jacqueline Mudd, Michael Ittmann, Carol J. Bult, Amanda R. Kirane, Jelena Randjelovic, Stephen Scott, Yige Wu, Li Ding, Vashisht G. Yennu-Nanda, Jing Wang, Christopher D. Lanier, Maihi Fujita, Emilio Cortes-Sanchez, Sienna Rocha, Susan G. Hilsenbeck, Kian-Huat Lim, Fernanda Martins Rodrigues, Jill Rubinstein, Nicholas Mitsiades, Haiyin Lin, Jayamanna Wickramasinghe, Andrew Butterfield, Bryan E. Welm, Alana L. Welm, Jose P. Zevallos, Jason Held, Nicole B. Coggins, Song Cao, Yuanxin Xi, Brenda C. Timmons, Paul Lott, David Menter, Shunqiang Li, Tina Primeau, Fei Yang, Andrea Wang-Gillam, Ramaswamy Govindan, Dali Li, Brandi Davis-Dusenbery, Sara Seepo, Michael C. Wendl, Jeffrey Grover, Brian S. White, Clifford G. Tepper, Peter N. Robinson, Michael A. Davies, Zhengtao Chu, Michael W. Lloyd, Hua Sun, Xiaoshan Zhang, Tamara Stankovic, Dylan Fingerman, Anuj Srivastava, Luis G. Carvajal-Carmona, Don L. Gibbons, Lijun Yao, Rebecca Aft, Hongyong Zhang, Ismail Meraz, John DiGiovanna, Scott Kopetz, Ling Zhao, Guadalupe Polanco-Echeverry, Feng Chen, Jeremy Hoog, Matthew A. Wyczalkowski, George Xu, John D. Minna, Yi Xu, Julie Belmar, Xiaowei Xu, Luc Girard, Dennis A. Dean, Tijana Borovski, Chong-xian Pan, Cynthia X. Ma, Alexa Morales Arana, Yize Li, Turcin Saridogan, Steven B. Neuhauser, Sandra Scherer, Vicki Chin, Rose Tipton, David R. Gandara, Sherri R. Davies, Argun Akcakanat, Rajesh Patidar, Julie K. Schwarz, Soner Koc, Gao Boning, Michael Kim, Bryce P. Kirby, Yvonne A. Evrard, Hyunsil Park, Christian Frech, Chia-Kuei Mo, Ran Zhang, Brian A. Van Tine, Jonathan W. Reiss, Min Xiao, Xing Yi Woo, Tiffany Le, Ana Estrada, Xiaofeng Zheng, Jeffrey A. Moscow, Mourad Majidi, Nadezhda V. Terekhanova, Katherine Fuh, Erkan Yuca, Timothy A. Yap, Jianhua Zhang, Matthew J. Ellis, Shannon Westin, James H. Doroshow, Vito W. Rebecca, Moon S. Chen, Coya Tapia, Reyka G Jayasinghe, Jack A. Roth, Jithesh Augustine, Ryan C. Fields, Michae T. Tetzlaff, Michael T. Lewis, Kurt W. Evans, Ralph W. deVere White, Brian J. Sanderson, May Cho, Jeffrey H. Chuang, Tiffany Wallace, Ryan Jeon, Ted Toal, Matthew H. Bailey, Bert W. O'Malley, Katherine L. Nathanson, Qin Liu, Benjamin J. Raphael, Jingqin Luo, Salma Kaochar, Huiqin Chen, Rajasekharan Somasundaram, Daniel Cui Zhou, John F. DiPersio, Andrew V. Kossenkov, Bingliang Fang, Vanessa Jensen, Simone Zaccaria, Alexey Sorokin, Ai-Hong Ma, Sidharth V. Puram, Min Jin Ha, Meenhard Herlyn, R. Jay Mashl, Kelly Gale, Bingbing Dai, Lacey E. Dobrolecki, Chieh-Hsiang Yang, and Funda Meric-Bernstam

Subjects
endocrine system, Science, Druggability, General Physics and Astronomy, Genomics, Computational biology, Biology, Genome, digestive system, General Biochemistry, Genetics and Molecular Biology, Article, Research community, Multiple time, medicine, Cancer genomics, Cancer models, Tumor xenograft, Multidisciplinary, Cancer, General Chemistry, medicine.disease, Pharmacogenomics, Data integration, hormones, hormone substitutes, and hormone antagonists
Abstract

Development of candidate cancer treatments is a resource-intensive process, with the research community continuing to investigate options beyond static genomic characterization. Toward this goal, we have established the genomic landscapes of 536 patient-derived xenograft (PDX) models across 25 cancer types, together with mutation, copy number, fusion, transcriptomic profiles, and NCI-MATCH arms. Compared with human tumors, PDXs typically have higher purity and fit to investigate dynamic driver events and molecular properties via multiple time points from same case PDXs. Here, we report on dynamic genomic landscapes and pharmacogenomic associations, including associations between activating oncogenic events and drugs, correlations between whole-genome duplications and subclone events, and the potential PDX models for NCI-MATCH trials. Lastly, we provide a web portal having comprehensive pan-cancer PDX genomic profiles and source code to facilitate identification of more druggable events and further insights into PDXs’ recapitulation of human tumors., Patient-derived xenograft models (PDX) have been extensively used to study the molecular and clinical features of cancers. Here the authors present a cohort of 536 PDX models from 25 cancers, as well as their genomic and evolutionary profiles and their suitability for clinical trials.

Published
2021

15. B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma

Author

Heinz Läubli, Florian Roka, Meenhard Herlyn, Thomas Wiesner, Rajasekharan Somasundaram, Stephan N. Wagner, Peter Petzelbauer, Gao Zhang, Markus Hartl, Katharina Glatz, Christine Wagner, Martin Simon, Johannes Griss, Wolfgang Bauer, Margarita Maurer-Granofszky, Thomas Penz, Katharina Grabmeier-Pfistershammer, Winfried F. Pickl, Christoph Bock, Minyi Chen, Peter Steinberger, and Kirsten D. Mertz

Subjects
0301 basic medicine, Cancer microenvironment, T cell, medicine.medical_treatment, Science, Programmed Cell Death 1 Receptor, General Physics and Astronomy, Inflammation, CD8-Positive T-Lymphocytes, In Vitro Techniques, General Biochemistry, Genetics and Molecular Biology, CCL5, Article, 03 medical and health sciences, 0302 clinical medicine, Cell Line, Tumor, medicine, Humans, lcsh:Science, Chemokine CCL4, Chemokine CCL5, Melanoma, 030304 developmental biology, Chemokine CCL3, 0303 health sciences, B-Lymphocytes, Multidisciplinary, business.industry, Antibodies, Monoclonal, General Chemistry, Immunotherapy, medicine.disease, Immune checkpoint, 3. Good health, Blockade, 030104 developmental biology, medicine.anatomical_structure, 030220 oncology & carcinogenesis, Cancer research, Tumour immunology, lcsh:Q, medicine.symptom, business, CD8
Abstract

Tumor associated inflammation predicts response to immune checkpoint blockade in human melanoma. Current theories on regulation of inflammation center on anti-tumor T cell responses. Here we show that tumor associated B cells are vital to melanoma associated inflammation. Human B cells express pro- and anti-inflammatory factors and differentiate into plasmablast-like cells when exposed to autologous melanoma secretomes in vitro. This plasmablast-like phenotype can be reconciled in human melanomas where plasmablast-like cells also express T cell-recruiting chemokines CCL3, CCL4, CCL5. Depletion of B cells in melanoma patients by anti-CD20 immunotherapy decreases tumor associated inflammation and CD8+ T cell numbers. Plasmablast-like cells also increase PD-1+ T cell activation through anti-PD-1 blockade in vitro and their frequency in pretherapy melanomas predicts response and survival to immune checkpoint blockade. Tumor associated B cells therefore orchestrate and sustain melanoma inflammation and may represent a predictor for survival and response to immune checkpoint blockade therapy., The regulation of tumor inflammation is incompletely understood and the role of B cells is unclear. Here, the authors show that a specific subtype of B cells is induced in melanoma and required to recruit T lymphocytes and elicit inflammation.

Published
2019

16. Author Correction: Loss of Phd2 cooperates with BRAF V600E to drive melanomagenesis

Author

Liyun Dong, Brett L. Ecker, Gao Zhang, Jingce Lei, Gordon B. Mills, Cheng Feng, Caitlin Feltcher, Daisheng Song, Suresh M. Kumar, Rebecca Lee, Jianping Guo, James S. Martin, Xiangpeng Dai, Zhi Wei, Lunquan Sun, Jie Zhang, Yiling Lu, Kai Peng, Ashani T. Weeraratna, Jingwen Niu, Xiaoming Liu, Heddy Kerestes, Kan Ze, Frank S. Lee, Xiang Chen, Yang Gao, Wenyi Wei, Wei Guo, Meenhard Herlyn, Lin Zhang, Ruifeng Yang, Hui Chen, Weiting Xu, Shujing Liu, and Xiaowei Xu

Subjects
Multidisciplinary, business.industry, Published Erratum, Science, MEDLINE, General Physics and Astronomy, General Chemistry, computer.software_genre, General Biochemistry, Genetics and Molecular Biology, Spelling, BRAF V600E, lcsh:Q, Artificial intelligence, lcsh:Science, business, Psychology, computer, Natural language processing
Abstract

The original version of this Article contained an error in the spelling of the author Brett L. Ecker, which was incorrectly given as Brett Ecker. This has now been corrected in both the PDF and HTML versions of the Article.

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results